People: GlaxoSmithKline PLC (GLAXF.PK)
26.12USD
21 May 2013
$-0.11 (-0.42%)
$26.23
$26.12
$26.12
$26.12
145
5,688
$26.29
$20.67
Vallance, Patrick
Brief Biography
Mr. Patrick Vallance is President - Pharmaceuticals R&D of Glaxosmithkline Plc. He was appointed President, Pharmaceuticals R&D, in January 2012. Prior to his appointment he was Senior Vice President, Medicines Discovery and Development. Patrick joined the company in 2006 as Head of Drug Discovery. Prior to joining GSK Patrick was a clinical academic at University College London. Patrick is a member of the Board of the Agency for Science, Technology & Research (A*STAR) and is a director of Genome Research Limited. He is also a member of the International Scientific Advisory Board of the Cambridge Institute for Medical Research.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Christopher Gent |
675,000 |
Andrew Witty |
3,892,000 |
Simon Dingemans |
1,186,000 |
Moncef Slaoui |
4,610,000 |
Deirdre Connelly |
-- |
Roger Connor |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
